| Industry sponsored symposia Auditorium |
||
| 09.45 - 10.30 | MONDAY JUNE 9 | |
 |
||
| HTN Technology matters | ||
| Chairman: Max Amor | ||
| Return on experience Renal denervation: technology and perspectives, Jean-Pascal Peyre The Vessix Technology, Piero Montorsi  |
||
| 14.15 - 15.50 | MONDAY JUNE 9 | |
| Meet the companies: Hot topics & the newest interventional techniques |
||
| Moderators: C. Mialhe, R. McWilliams, F. Setacci |
||
| 14.15 - Sustained durability of the new generation stent graft: the Endurant case example. Presenting the results of the ENGAGE registry at 3 years, A. Sauguet |
||
| 14.25 - Treating EVAR challenging anatomy with anatomical fixation, J-P. de Vries | ||
| 14.35 - A novel carotid artery stent for sustained embolic protection, M. Amor | ||
| 14.55 - New devices (S.M.A.R.T® Flex and SABER™ .018) for PAD treatment and BTK, E. Ducasse |
||
| 15.15 - BATTLE: the rationale for comparing BMS and DES, Y. Gouëffic | ||
| 15.25 - New perspectives in Atherectomy and Thrombectomy, TBC | ||
| 15.35 - New Use of 4 Fr SES for peripheral treatment: options and advantages, E. Ducasse | ||
| 15.45 - Treatment of arterial and venous occlusions with Rotarex and Aspirex mechanical debulking, M. Amor | ||
| 16.30 - 17.15 | MONDAY JUNE 9 | |
 |
||
| Current endovascular treatment of the SFA | ||
| Chairman: Max Amor | ||
| Speakers: Massimiliano Di Primio, Jonathan Sobocinski | ||
| Review of recent clinical data Unique character of the SFA and the different stent designs Review of the current treatment options Abbott Vascular current and future solutions |
||
| 10.00 - 10.45 | TUESDAY JUNE 10 | |
 |
||
| Prime time for drug eluting balloons? Hard facts and recent outcomes |
||
| Chairmen: Max Amor, Yann Gouëffic Introduction and objectives Latest Evidence about In.Pact DEB usage in fempop segment, Gunnar Tepe Role of stenting in DEB era, Marianne Broadman Panel discussion & take home messages |
||
